SEP 1 0 2002

KOZZ664

p.21

# ARC Medical Supplies(Beijing) Co., Ltd.

#66 Qian Ban Bi Jie, Xizhimen Nei, Beijing CHINA 100035 Tel: 8610-6617 8581 Fax: 8610-66113481 Email: arcmedic <u>a public.bta.net.en</u>

Page 1 of 2

### 510(k) SUMMARY

This summary of safety and effectiveness information is being submitted in accordance with the requirements of SMDA 1990 and 21 CFR 807.92

The assigned 510(k) number is: \_\_\_\_\_\_.

<u>Applicant</u>	ARC Medical Supplies (Beijing) Co., Ltd. #66 Quian Ban Bi Jie, Xizhimen Nei Beijing, China 100035 Telephone: 8610 6617 8581 Fax: 8610 6611 3481
Contact Person	Mr. Charles F. Andrews C.F. Andrews & Associates 1591 S. Moorland Road, Suite 104 New Berlin, WI 53151 Telephone: (414) 416-9119 Fax: (414) 389-1650
Date	August 7, 2002
Name of Device	
Proprietary Name:	PGA (Polyglycolic) Synthetic Absorbable Suture U.S.P.
Common or Usual Name:	Absorbable suture, synthetic absorbable suture, PGA suture
Classification Name:	Suture, Absorbable, Synthetic, Polyglycolic Acid

KC22664

## ARC Medical Supplies(Beijing) Co., Ltd.

#66 Qian Ban Bi Jie, Xizhimen Nei, Beijing CHINA 100035 Tel: 8610-6617 8581 Fax: 8610-66113481 Email: arcmedic: a public.bta.net.en

Page 2 of 2

#### 510(k) SUMMARY - continued

PGA (Polyglycolic) Synthetic Absorbable Sutures, U.S.P. manufactured by ARC Medical Supplies (Beijing) Co., Ltd. are equivalent to SURGISORB absorbable surgical sutures manufactured by SAMYANG Corporation.

The PGA (Polyglycolic) Synthetic Absorbable Sutures, U.S.P. manufactured by ARC Medical and SAMYANG Corporation are braided and monofilament types and coated with polycaprolate and calcium stearate and are un-dyed or dyed with D&C Violet No. 2.

PGA (Polyglycolic) Synthetic Absorbable Sutures are indicated for use in general soft tissue approximation; including use in ophthalmic surgery but not for use in cardiovascular and neurological tissue.

Testing of suture diameter, suture length, knot pull tensile strength, needle attachment strength and absorption rate according to methods outlined in U.S.P. XXIII demonstrates that ARC Medical PGA (Polyglycolic) Synthetic Absorbable sutures meet or exceed U.S.P. specifications and are equivalent in terms of the above parameters to synthetic absorbable polyglycolic surgical sutures manufactured by SAMYANG Corporation.

- 3-6-02

Richard Kuo, Chairman

Date

#### DEPARTMENT OF HEALTH & HUMAN SERVICES



SEP 1 0 2002

Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850

ARC Medical Supplies (Beijing) Company, LTD. c/o C.F. Andrews & Associates Charles F. Andrews 1591 S. Moorland Road, Suite 104 New Berlin, Wisconsin 53151

Re: K022664

Trade/Device Name: PGA (Polyglycolic) Synthetic Absorable Suture U.S.P. Regulation Number: 878.4493 Regulation Name: Absorbable poly(glycolide/L-lactide) surgical suture Regulatory Class: Class II Product Code: GAM Dated: August 7, 2002 Received: August 9, 2002

Dear Mr. Andrews:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

Page 2 – Mr. Charles F. Andrews

This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 21 CFR Part 809.10 for <u>in vitro</u> diagnostic devices), please contact the Office of Compliance at (301) 594-4659. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address http://www.fda.gov/cdrh/dsma/dsmamain.html

Sincerely yours,

Witten, Ph.D., M.D.

Director Division of General, Restorative and Neurological Devices Office of Device Evaluation Center for Devices and Radiological Health

Enclosure

K022664

## IX. INDICATIONS FOR USE

PGA (polyglycolic) Synthetic Absorbable Sutures U.S.P. are indicated for use in general soft tissue approximation; including use in ophthalmic surgery, but not for use in cardiovascular and neurological tissue.

(Division Sigh-Off) Division of General, Restorative and Neurological Devices

4022664 510(k) Number